Your browser doesn't support javascript.
loading
Case report: Spontaneous improvement and treatment considerations in leukoencephalopathy with calcifications and cysts.
Beerepoot, Shanice; Ardon, Hilko; Niers, Anneke; van der Knaap, Marjo S.
Afiliação
  • Beerepoot S; Department of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, the Netherlands; Amsterdam Neuroscience, Cellular & Molecular Mechanisms, Amsterdam University Medical Center, Amsterdam, the Netherlands; Department of Integ
  • Ardon H; Department of Neurosurgery, St. Elisabeth Hospital, Tilburg, the Netherlands; Department of Integrative Neurophysiology, Center for Neurogenomics and Cognitive Research, Vrije Universiteit, Amsterdam, the Netherlands.
  • Niers A; Department of Neuro Oncology, Amsterdam University Medical Center, Amsterdam, the Netherlands; Department of Integrative Neurophysiology, Center for Neurogenomics and Cognitive Research, Vrije Universiteit, Amsterdam, the Netherlands.
  • van der Knaap MS; Department of Child Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, the Netherlands; Amsterdam Neuroscience, Cellular & Molecular Mechanisms, Amsterdam University Medical Center, Amsterdam, the Netherlands; Department of Integ
Clin Neurol Neurosurg ; 245: 108517, 2024 Oct.
Article em En | MEDLINE | ID: mdl-39173493
ABSTRACT
We present the case of a patient with leukoencephalopathy with calcifications and cysts (LCC), who experienced progressive severe hemiparesis despite multiple neurosurgical interventions of a large contralateral cyst. Bevacizumab was proposed as an ultimate treatment option based on prior case reports. While awaiting reimbursement approval for bevacizumab, major improvement occurred in both clinical and radiological disease manifestations. The disease course of LCC is variable and unpredictable; neurosurgical treatment should be reserved for severe and progressive neurological deficits. Bevacizumab has been reported as a promising alternative treatment option. Importantly, in our case the observed clinical improvement would have been attributed to the effects of bevacizumab, if started when requested. Our case underscores the need for a natural history study for LCC and the necessity of validating treatment efficacy by systematic evaluation through appropriate clinical trials rather than relying on anecdotal evidence from published case reports.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Calcinose / Leucoencefalopatias Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Calcinose / Leucoencefalopatias Idioma: En Ano de publicação: 2024 Tipo de documento: Article